Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers

Aims: The EMPA-REG OUTCOME trial demonstrated that the sodium-glucose cotransporter-2 inhibitor (SGLT2) empagliflozin reduces the risk of cardiovascular (CV) and kidney outcomes in patients with type 2 diabetes. We previously developed the parameter response efficacy (PRE) score, which translates dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tye, Sok Cin, de Vries, Sieta T., Wanner, Christoph, Denig, Petra, Heerspink, Hiddo J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821652/
https://www.ncbi.nlm.nih.gov/pubmed/35145402
http://dx.doi.org/10.3389/fphar.2021.786706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821652/
https://www.ncbi.nlm.nih.gov/pubmed/35145402
http://dx.doi.org/10.3389/fphar.2021.786706

Ejemplares similares